A combined approach targeting ER, HER2, and RB1 yielded promising results in terms of Ki-67 expression in women with HER2-positive, ER-positive breast cancer.
ImmunoMap, which can examine T-cell receptor repertoire relatedness, may help predict clinical outcome for patients with cancer and could be a new tool for designing vaccines and immunotherapies.
A comparison of margin classification systems revealed some differences in their ability to determine local recurrence risk for soft-tissue sarcoma.
Use of stereotactic ablative radiotherapy effectively treated patients with primary renal cell carcinoma and had an acceptable effect on patient renal function.
Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy.
No difference was found in pathologic complete response rates between neoadjuvant paclitaxel and nab-paclitaxel in women with ERBB2/HER2-negative breast cancer.
The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with bone metastases and multiple myeloma.
ASCO recently released a clinical practice guideline on the treatment of malignant pleural mesothelioma, including recommendations on diagnosis, staging, and treatment with chemotherapy, surgical cytoreduction, and radiation therapy.
The time to testosterone rebound was associated with differences in prostate cancer–specific and cardiovascular mortality among men who underwent RT and ADT.
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.